KCC-07|CAS |DC Chemicals

Cas No.:	315702-75-1
Chemical Name:	3-{[4-(2-Pyridinyl)-1,3-thiazol-2-yl]amino}phenol
Synonyms:	3-{[4-(pyridin-2-yl)-1,3-thiazol-2-yl]amino}phenol;CBMicro_027305;Oprea1_718651;KCC 07;BDBM158506;NSC752630;US9034574, II;ST50028583;3-[[4-(2-Pyridinyl)-2-thiazolyl]amino]phenol;3-[(4-(2-pyridyl)-1,3-thiazol-2-yl)amino]phenol;3-{[4-(2-pyridinyl)-1,3-thiazol-2-yl]amino}phenol;3-(4-Pyridin-2-yl-thiazol-2-ylamino)-phenol;NS-04313;KCC-07
SMILES:	S1C=C(C2C=CC=CN=2)N=C1NC1C=CC=C(C=1)O
Formula:	C₁₄H₁₁N₃Os
M.Wt:	269.321641206741
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:	KCC-07 is a potent, selective and brain-penetrant inhibitor of MBD2 (methyl-CpG-binding domain protein 2) with anticancer activity. It prevents binding of MBD2 to methylated DNA and activates brain specific angiogenesis inhibitor 1 (BAI1) inducing anti-proliferative BAI1/p53/p21 signaling.
Target:	MBD2 (methyl-CpG-binding domain protein 2)[1]
In Vivo:	KCC-07 (100 mg/kg; intraperitoneal injection; 5 days/week; athymic nude mice) treatment inhibits tumor growth and significantly extends the survival of MB xenografts in vivo[1]. Animal Model: Outbred athymic nude mice (females; 8-10 weeks old) injected with MB cells[1] Dosage: 100 mg/kg Administration: Intraperitoneal injection; 5 days/week Result: Significantly extended the survival of MB xenografts in vivo.
In Vitro:	KCC-07 (10 μM; 72 hours; MB cells) treatment clearly inhibited MB cell growth in vitro, consistent with induction of anti-proliferative BAI1/p53/p21 signaling[1]. KCC-07 (10 μM; 48 hours; MB cells) treatment largely abrogates MBD2 binding to the ADGRB1 promoter and restores BAI1 mRNA and protein expression in BAI1-silent MB cells[1]. Cell Viability Assay[1] Cell Line: Medulloblastomas (MB) cells Concentration: 10 μM Incubation Time: 72 hours Result: Clearly inhibited MB cell growth in vitro. Western Blot Analysis[1] Cell Line: Medulloblastomas (MB) cells Concentration: 10 μM Incubation Time: 48 hours Result: Largely abrogated MBD2 binding to the ADGRB1 promoter in BAI1-silent MB cells.
References:	[1]. Dan Zhu, et al. BAI1 Suppresses Medulloblastoma Formation by Protecting p53 From Mdm2-Mediated Degradation. Cancer Cell. 2018 Jun 11;33(6):1004-1016.e5.

Cat. No.	Product name	Field of application
DC31074	Isopropyl myristate	Isopropyl myristate is the ester of isopropyl alcohol and myristic acid.
DC75868	AZ14133346	AZ14133346 (compound 36) is a potent and selective inhibitor of EGFR Exon20 insertions, with the IC50 of 85 nM. AZ14133346 plays an important role in cancer research.
DC75865	TI17	TI17 represents a novel class of targeted anticancer agents that specifically disrupt DNA damage repair mechanisms in malignant cells.
DC75816	Nisoxetine	Nisoxetine acts as a highly selective and potent noradrenaline transporter (NET) antagonist, exhibiting a binding affinity (Kd) of 0.76 nM. In addition to its antidepressant properties, nisoxetine functions as a local anesthetic by inhibiting voltage-gated sodium channels. This dual pharmacological activity makes it a compound of interest for both neurological and pain management research.
DC75641	GENZ-644282 TFA salt	Genz-644282, also known as SAR402674, is a non-camptothecin inhibitor of topoisomerase I with potential antineoplastic activity. Topoisomerase I inhibitor Genz-644282 binds to and inhibits the enzyme topoisomerase I, which may result in the inhibition of repair of single-strand DNA breaks, DNA replication, and tumor cell growth in susceptible tumor cell populations.
DC75325	PSMA-617 TFA	PSMA-617, also know as vipivotide tetraxetan, is a ligand used to make 177Lu-PSMA-617, which is a radioactive molecule to fight cancer. PSMA617 possesses a small peptide, which was designed to target prostate-specific membrane antigen (PSMA). PSMA617 demonstrates high radiolytic stability for at least 72 h. PSMA617 has high inhibition potency (equilibrium dissociation constant Ki=2.34±2.94 nM on LNCaP; Ki=0.37±0.21 nM enzymatically determined). 177 Lu-PSMA-617 offers a potential additional life-prolonging treatment option for men with mCRPC.
DC75202	Fosaprepitant free acid	Fosaprepitant, also known as MK0517, is an antiemetic drug, administered intravenously. It is a prodrug of aprepitant. Fosaprepitant was developed by Merck & Co. and was approved. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment. Fosaprepitant is a weak inhibitor of CYP3A4, and aprepitant, the active moiety, is a substrate, inhibitor, and inducer of CYP3A4
DC74748	O4I4	O4I4 (compound 23) is a OCT4-inducing compound with metabolical stability.
DC74684	ZH8667	ZH8667 is a trace amine-associated receptor 1 (TAAR1)–Gs agonist.
DC74646	EB-PSMA-617	EB-PSMA-617 is an Evans blue-modified prostate-specific membrane antigen (PSMA) 617 ligand for making 177Lu-EB-PSMA, which is potential useful for Metastatic Castration-Resistant Prostate Cancer.